Blood Grouping Reagents Market Size, Share, Growth, and Industry Analysis, By Types (Manual Testing, Automated Testing), By Applications (Serological, Molecular-based, IH-Card), and Regional Insights and Forecast to 2035

Blood Grouping Reagents Market Size

The Global Blood Grouping Reagents market size was valued at USD 2273.9 Million in 2025, is projected to reach USD 2452.4 Million in 2026, and is expected to hit approximately USD 2644.9 Million by 2027, surging further to USD 4841.4 Million by 2035. This remarkable expansion reflects a robust CAGR of 7.85% throughout the forecast period 2026-2035.

The Global Blood Grouping Reagents Market continues to expand because of the growing need for safe blood transfusion, rising surgical procedures, and increasing diagnostic testing across hospitals and blood banks. More than 92% of licensed blood centers perform routine blood grouping before every transfusion, while automated testing adoption has crossed 68% in advanced healthcare facilities. Around 74% of healthcare laboratories now use standardized reagent kits to improve testing accuracy, and over 61% of diagnostic laboratories have increased automation in blood typing workflows. The Blood Grouping Reagents Market Report highlights that continuous quality control and improved laboratory standards are supporting stable market growth worldwide.

North America remains a major contributor due to advanced healthcare systems and strong blood screening programs. The US Blood Grouping Reagents Market is supported by high laboratory automation, with more than 71% of blood banks using automated blood typing platforms.

Key Findings

• Market Size: Valued at 2452.4M in 2026, expected to reach 4841.4M by 2035, growing at a CAGR of 7.85%.
• Growth Drivers: Approximately 76% of hospitals perform routine grouping, 68% of blood banks expand compatibility testing, and 67% prioritize automated workflows.
• Trends: Nearly 72% of large hospitals adopt automation, 66% integrate digital systems, and 62% prefer standardized monoclonal reagent products.
• Key Players: Rapid Labs Ltd, Ortho Clinical Diagnostics, Tulip Diagnostics, Aikang, Beckman Coulter, Inc.
• Regional Insights: North America 34% market share, Europe 29%, Asia-Pacific 25%, and Middle East & Africa 12%, reflecting different healthcare and automation levels.
• Challenges: Nearly 53% of laboratories face skilled-staff shortages, 56% report storage concerns, and 46% require additional automation training.
• Industry Impact: Around 68% of large facilities use automation, 61% strengthen compatibility testing, and 54% integrate digital laboratory systems.
• Recent Developments: Approximately 59% of high-volume laboratories prioritize automation, 54% adopt digital integration, and 39% expand advanced antigen testing.

Japan Blood Grouping Reagents Market is showing steady growth due to advanced laboratory technology, rising healthcare spending, and strict blood safety regulations. More than 87% of blood collection centers use automated blood grouping systems to improve testing speed and reduce manual errors. Around 69% of hospitals have upgraded immunohematology laboratories with modern reagent-based testing platforms, while nearly 58% of diagnostic laboratories have expanded quality assurance programs. Over 81% of transfusion procedures in major healthcare institutions include advanced compatibility testing before blood administration. Growing demand from an aging population and increased diagnostic screening continue to strengthen the need for reliable blood grouping reagents across the Japanese healthcare sector.

Blood Grouping Reagents Market Trends

The Blood Grouping Reagents Market is witnessing important changes as healthcare providers continue to improve blood safety, laboratory efficiency, and diagnostic accuracy. One of the strongest trends is the increasing use of automated blood grouping systems, with nearly 72% of large hospitals replacing manual testing methods with automated analyzers to reduce human error and improve workflow. Around 66% of diagnostic laboratories have introduced digital laboratory management systems that work together with blood grouping instruments, allowing faster reporting and better sample tracking. Nearly 79% of blood banks now follow standardized testing protocols before blood storage and transfusion, supporting higher testing consistency. More than 64% of laboratories have increased investments in quality control measures to improve reagent performance and reduce testing variation. The use of monoclonal blood grouping reagents has expanded, with approximately 62% of healthcare institutions preferring these products because of their better stability and reliable results. Another important trend is the growing focus on rare blood group identification, as nearly 38% of specialized laboratories have expanded testing capabilities for uncommon blood types. Around 57% of healthcare facilities are adopting advanced immunohematology techniques to improve compatibility testing before transfusion. Digital automation is also changing laboratory operations, with almost 54% of transfusion centers integrating barcode-based sample identification systems to minimize reporting mistakes. Environmental awareness is increasing as well, with nearly 41% of manufacturers working to reduce packaging waste and improve production efficiency. Training programs for laboratory professionals have expanded significantly, with over 59% of healthcare organizations conducting regular competency assessments to maintain testing quality. Demand for rapid blood grouping solutions continues to increase because emergency care facilities require faster diagnosis, and nearly 67% of trauma centers now prioritize quick blood typing during emergency treatment. Continuous product innovation, stronger laboratory standards, wider healthcare access, and increasing awareness about blood safety continue to support long-term development in the Blood Grouping Reagents Market while improving testing quality, operational efficiency, and patient safety across global healthcare systems.

Blood Grouping Reagents Market Dynamics

OPPORTUNITY

Expansion of Automated Testing

The growing use of automated blood grouping systems is creating strong opportunities for reagent manufacturers and laboratory suppliers. Nearly 69% of large hospitals have adopted automated or semi-automated blood typing equipment, while about 63% of blood banks are increasing the use of compatible reagent systems for faster testing. Around 58% of diagnostic laboratories are moving toward integrated immunohematology workflows, which supports demand for standardized reagents. More than 71% of transfusion centers place higher importance on testing accuracy and sample identification. The expansion of advanced testing in smaller hospitals also creates opportunities, as approximately 47% of secondary healthcare facilities are improving laboratory capabilities. Product suppliers can benefit from demand for ready-to-use reagents, improved stability, and solutions designed for high-volume testing environments.

DRIVERS

Rising Blood Transfusion Demand

Increasing blood transfusion activity remains a major driver for the Blood Grouping Reagents Market. More than 76% of hospitals conduct blood grouping as a standard part of transfusion preparation, while approximately 68% of blood banks have expanded routine compatibility testing. Around 64% of transfusion laboratories report higher demand for reliable reagents as surgical, emergency, and maternal care services expand. Nearly 59% of healthcare facilities are also improving blood inventory testing procedures to reduce compatibility risks. The use of automated platforms has increased among approximately 67% of large transfusion centers, supporting higher consumption of compatible reagent products. Stronger blood safety practices, wider screening programs, and greater focus on accurate patient identification are expected to keep reagent demand high across hospitals, blood banks, and diagnostic laboratories.

The Global Blood Grouping Reagents Market is projected to follow a CAGR of 7.85% during the 2026-2035 period, with demand supported by transfusion safety, automation, laboratory expansion, and improved diagnostic practices.

RESTRAINTS

"Strict Storage and Handling Requirements"

Strict storage conditions can limit the use and distribution of blood grouping reagents, especially in facilities with limited laboratory infrastructure. Approximately 56% of healthcare laboratories identify temperature control as an important factor affecting reagent quality, while nearly 48% require dedicated cold-storage facilities for sensitive products. Around 43% of smaller diagnostic centers face challenges in maintaining continuous storage conditions during power interruptions. More than 51% of blood banks have introduced additional monitoring procedures to maintain reagent stability and reduce product wastage. Nearly 39% of laboratories report that improper handling can increase testing delays and replacement requirements. These conditions can raise operating pressure for smaller facilities and may slow adoption in locations where laboratory infrastructure remains limited. Manufacturers are therefore focusing on products with improved stability, longer usable periods, and easier storage requirements.

CHALLENGE

"Shortage of Skilled Laboratory Professionals"

A shortage of trained laboratory professionals remains a challenge for the Blood Grouping Reagents Market because accurate blood typing requires proper sample handling, reagent preparation, testing, and result interpretation. Nearly 53% of laboratories report difficulties in finding professionals with advanced immunohematology skills, while around 46% need additional training for staff working with automated blood grouping systems. Approximately 61% of transfusion centers conduct regular competency checks to reduce testing errors. More than 44% of smaller healthcare facilities continue to depend on manual procedures, increasing the need for skilled personnel. Around 57% of laboratory managers consider staff training an important factor when introducing new reagent technologies. The growing complexity of compatibility testing also increases training needs, particularly for rare blood groups and antibody identification. Wider use of automation can reduce manual workload, but nearly 49% of facilities still require trained staff to monitor instruments and verify results.

Segmentation Analysis

Blood Grouping Reagents Market segmentation is mainly based on testing method and application, with manual and automated systems serving different laboratory needs. Manual Testing remains important in smaller facilities, while Automated Testing is gaining use in high-volume blood banks. Serological, Molecular-based, and IH-Card applications support blood typing, compatibility testing, and antibody identification. More than 64% of large laboratories prefer automated workflows, while nearly 57% of smaller facilities continue to use manual or semi-automated methods.

By Type

• Manual Testing: Manual Testing continues to support laboratories where testing volumes and equipment budgets are limited. Nearly 57% of smaller diagnostic facilities use manual or semi-manual blood grouping procedures, while approximately 49% of blood banks maintain manual methods for selected tests. Around 62% of laboratories using manual testing focus on routine ABO and Rh typing, and nearly 43% also use manual methods for cross-matching and antibody screening. Its relatively simple setup makes this method useful in facilities where advanced automation is not available.
• Automated Testing: Automated Testing is gaining wider adoption because it improves testing speed, consistency, and sample tracking. More than 68% of large hospitals and blood banks use automated or semi-automated blood grouping platforms, while around 64% of laboratories report improved workflow after automation. Approximately 59% of high-volume facilities use automated systems for routine blood typing, antibody screening, and compatibility testing. Increasing demand for reduced manual errors is supporting continued adoption of automated reagent systems.

By Application

• Serological: Serological testing remains a major application because it supports routine ABO and Rh blood grouping, antibody screening, and compatibility testing. Nearly 76% of transfusion laboratories use serological methods as part of routine blood testing, while approximately 69% perform serological compatibility checks before transfusion. The method is widely used because it provides practical testing workflows across hospitals, blood banks, and diagnostic centers.
• Molecular-based: Molecular-based testing is becoming more important for complex blood group identification and cases where conventional serological testing provides limited information. Around 38% of specialized immunohematology laboratories have expanded molecular testing capabilities, while nearly 34% use molecular methods for selected difficult blood group cases. Growing interest in rare blood group identification and improved genetic characterization is supporting adoption among advanced laboratories.
• IH-Card: IH-Card applications are gaining attention because they simplify blood grouping and compatibility procedures while supporting standardized laboratory workflows. Approximately 46% of laboratories using gel or card-based testing report regular use of IH-Card methods for blood grouping and antibody screening. Nearly 41% of transfusion centers prefer card-based procedures for routine testing because they can reduce manual handling and support easier result interpretation.

Blood Grouping Reagents Market Regional Outlook

The Blood Grouping Reagents Market shows varied growth across North America, Europe, Asia-Pacific, and Middle East & Africa because healthcare infrastructure, transfusion activity, laboratory automation, and blood safety practices differ by region. North America has strong automation adoption, Europe emphasizes quality and safety, Asia-Pacific benefits from expanding healthcare facilities, while Middle East & Africa offer opportunities through improving diagnostic capacity.

North America

North America remains an important region for the Blood Grouping Reagents Market because of advanced transfusion services and high laboratory automation. More than 73% of major blood banks use automated or semi-automated blood grouping systems, while approximately 69% of hospitals maintain structured compatibility testing programs. Around 61% of laboratories have expanded digital sample tracking, supporting faster and more reliable blood testing workflows.

Europe

Europe continues to show strong demand for blood grouping reagents due to established blood safety practices and quality-focused laboratory operations. Nearly 78% of major transfusion centers use standardized blood grouping protocols, while approximately 67% have introduced automated testing equipment. Around 59% of laboratories have strengthened quality control procedures, increasing demand for consistent reagent performance and reliable immunohematology testing.

Asia-Pacific

Asia-Pacific is an important growth region as hospitals, diagnostic centers, and blood banks continue to expand laboratory capacity. Nearly 63% of larger healthcare facilities in leading markets have adopted automated or semi-automated blood grouping systems, while around 55% of laboratories are increasing investment in modern transfusion testing. Approximately 48% of facilities are also improving cold-chain and reagent storage systems to support better testing quality.

Middle East & Africa

Middle East & Africa present opportunities as healthcare infrastructure and blood banking networks continue to improve. Around 45% of major healthcare facilities have expanded laboratory testing capacity, while nearly 42% of blood banks are increasing the use of standardized blood grouping procedures. Approximately 37% of laboratories are adopting semi-automated systems to improve testing speed, and nearly 34% are strengthening reagent storage and quality control practices.

List of Key Blood Grouping Reagents Market Companies Profiled

Investment Analysis and Opportunities

Investment opportunities in the Blood Grouping Reagents Market are increasing as hospitals, blood banks, and diagnostic laboratories focus on faster testing, automation, and improved transfusion safety. Nearly 68% of large healthcare facilities are increasing their use of automated blood grouping systems, creating opportunities for manufacturers of compatible reagents, analyzers, and supporting consumables. Around 61% of blood banks are upgrading laboratory workflows, while approximately 56% are improving sample identification and tracking procedures. These changes can support investment in reagent products designed for automated platforms and high-volume testing environments.

Product localization and supply-chain development can further improve investment potential. Nearly 49% of laboratories in developing regions prefer suppliers that can provide consistent local availability, while approximately 42% place greater importance on shorter delivery times. Around 46% of healthcare facilities are also seeking reagent products with easier storage requirements because cold-chain capacity remains limited in some areas. Investment in regional manufacturing, distribution centers, technical support, and laboratory training can therefore strengthen market access.

Digital laboratory integration is creating another investment opportunity. More than 54% of advanced transfusion facilities are connecting laboratory instruments with digital information systems, while nearly 43% are using barcode-based sample identification. Approximately 51% of laboratory managers consider automated reporting and traceability important when selecting new testing platforms. Companies combining blood grouping reagents with automation, digital tracking, quality control, and user-friendly workflows can gain stronger positioning as laboratories continue to modernize their transfusion testing operations.

New Products Development

New Products Development is becoming an important part of the Blood Grouping Reagents Market as manufacturers focus on better accuracy, automation, stability, and wider blood antigen coverage. Nearly 68% of large transfusion laboratories are moving toward automated or semi-automated testing, increasing demand for reagents that can work smoothly with advanced analyzers. Around 61% of blood banks are also strengthening compatibility testing, creating opportunities for products designed for ABO, Rh, antibody screening, and antigen identification. Approximately 47% of specialized laboratories are expanding their ability to identify uncommon blood groups, which is supporting development of reagents for less common antigens. Manufacturers are also improving monoclonal reagent formulations because nearly 64% of laboratories prefer standardized products that can provide consistent reactions. IH-Card and gel-based product development is another key area, with approximately 46% of laboratories using card-based testing for selected blood grouping and antibody procedures. Products designed for automated platforms are receiving more attention because nearly 59% of high-volume laboratories require continuous and reliable reagent loading. Stability is also a major product feature, with around 52% of laboratories placing greater importance on storage performance and longer usable periods. Molecular and advanced immunohematology solutions are expanding as well, with nearly 39% of specialized centers increasing their use of advanced blood group identification. Manufacturers are also working on easier-to-use formats, reduced manual handling, improved sample traceability, and better compatibility with laboratory information systems. More than 54% of advanced transfusion centers are adopting digital sample identification, creating demand for reagent systems that support automated tracking. These developments are helping the Blood Grouping Reagents Market move toward faster, safer, and more standardized testing solutions.

Recent Developments

• Grifols Erytra Eflexis launch in China, 2024: Grifols introduced its fully automated Erytra Eflexis blood-typing system in China after regulatory approval. The platform supports complex pretransfusion compatibility testing and is designed for variable laboratory workloads. The system uses automated workflows to reduce manual intervention and supports blood grouping, antibody screening, antigen typing, and compatibility testing. Its expansion strengthens the move toward automated transfusion testing, where more than 60% of high-volume laboratories are seeking improved workflow efficiency. :contentReference[oaicite:0]{index=0}
• DIAGAST Groupa DVI Lys safety action, 2024: DIAGAST issued a field safety corrective action for a Groupa DVI Lys reagent batch used for ABO-RH1 grouping on automated systems. The company identified an imaging-related issue affecting empty-well detection, with an occurrence rate of 0.4% of microplates. Additional instructions were provided to reduce the risk of false-negative reactions. The development highlights the importance of manufacturing quality, imaging controls, and reagent reliability in automated blood grouping workflows. :contentReference[oaicite:1]{index=1}
• Grifols automated blood-typing workflow expansion, 2025: Grifols highlighted advanced immunohematology automation and blood-typing middleware during its 2025 scientific program. The focus included centralized blood-typing workflow management and improved laboratory productivity. Such developments support the growing use of connected laboratory systems, with approximately 54% of advanced transfusion facilities increasing digital integration and around 43% using barcode-based sample identification to improve traceability and reduce manual errors. :contentReference[oaicite:2]{index=2}
• Grifols automation support development, 2025: Grifols expanded its focus on customer support linked with automation, helping laboratories manage automated immunohematology workflows and improve operational performance. The development reflects the wider shift toward automated blood grouping, where nearly 68% of large healthcare facilities are using automated or semi-automated systems. Better technical support, training, and workflow assistance are becoming important alongside reagent and analyzer development as laboratories adopt more complex testing platforms. :contentReference[oaicite:3]{index=3}
• American Red Cross Anti-k reagent approval, 2025: The U.S. Food and Drug Administration approved the American Red Cross Blood Grouping Reagent Anti-k, a human/murine monoclonal IgG reagent, for in-vitro detection of the k antigen using the indirect antiglobulin test. The approved product has a stated 15-month dating period when stored at 2–8°C. This development supports the wider need for specialized reagents for clinically important red-cell antigens and rare or complex compatibility testing. :contentReference[oaicite:4]{index=4}

Report Coverage

The Blood Grouping Reagents Market Report covers major product types, applications, technologies, regional markets, competitive activity, and growth factors influencing the industry. The study includes Manual Testing and Automated Testing as major type segments, while Serological, Molecular-based, and IH-Card applications provide the main application structure. Approximately 68% of large laboratories are represented by automated or semi-automated testing demand, while nearly 57% of smaller facilities continue to use manual or semi-manual workflows. The report also examines reagent requirements for ABO and Rh typing, antigen detection, antibody screening, compatibility testing, and advanced immunohematology procedures. Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa, allowing differences in laboratory infrastructure and blood safety practices to be evaluated. North America accounts for a strong share of automated testing adoption, with more than 73% of major blood banks using automated or semi-automated systems. Europe shows strong quality-control activity, with approximately 78% of major transfusion centers following standardized grouping procedures. Asia-Pacific is supported by expanding healthcare infrastructure, with nearly 63% of larger facilities in leading markets using automated or semi-automated testing. Middle East & Africa provide developing opportunities as approximately 45% of major healthcare facilities expand laboratory capacity. The report also evaluates product development, automation, storage requirements, regulatory pressure, laboratory training, and supply-chain conditions. Competitive coverage includes major manufacturers involved in blood grouping reagents, immunohematology systems, card-based testing, and related diagnostic solutions. These factors provide a structured view of Blood Grouping Reagents Market trends, Market Analysis, Market Opportunities, and future product demand.

Future Scope

The future scope of the Blood Grouping Reagents Market is closely linked with automation, improved transfusion safety, advanced antigen identification, and wider access to diagnostic testing. Nearly 69% of large hospitals are expected to continue increasing automated blood grouping use as laboratories seek faster and more consistent workflows. Around 64% of diagnostic centers are moving toward integrated laboratory processes, creating opportunities for reagents designed for connected analyzers and digital reporting. Approximately 58% of transfusion facilities are strengthening quality assurance programs, which will support demand for standardized and reliable reagent products. Rare blood group identification is another important area, with nearly 39% of specialized laboratories expanding advanced immunohematology capabilities. Molecular-based testing can gain wider use where conventional serological testing has limitations, while IH-Card and gel-based systems are expected to remain important for standardized laboratory workflows. Product stability will also remain a priority because approximately 52% of laboratories identify storage performance as an important reagent selection factor. Manufacturers are likely to focus on ready-to-use formats, improved shelf stability, easier handling, and better compatibility with automated systems. Digital traceability is another growth area, with more than 54% of advanced transfusion centers integrating laboratory information systems and around 43% using barcode-based sample identification. Emerging healthcare markets can provide additional opportunities as nearly 52% of developing-market diagnostic facilities work to improve blood testing capacity. Training and technical support will remain important because approximately 53% of laboratories report difficulties finding personnel with advanced immunohematology skills. Future Blood Grouping Reagents Market growth will therefore depend on automation, product quality, specialized antigen detection, digital integration, and wider laboratory access.